PIPELINE
Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are expected to enter human trials in 2020/21.
Program portfolio & status
Low molecular weight mutant agnostic approaches